KIR2DL2/2DL3-E(35) alleles are functionally stronger than -Q(35) alleles. by Bari, Rafijul et al.
UCLA
UCLA Previously Published Works
Title
KIR2DL2/2DL3-E(35) alleles are functionally stronger than -Q(35) alleles.
Permalink
https://escholarship.org/uc/item/0qw7h2m2
Journal
Scientific reports, 6(1)
ISSN
2045-2322
Authors
Bari, Rafijul
Thapa, Rajoo
Bao, Ju
et al.
Publication Date
2016-03-31
DOI
10.1038/srep23689
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRts | 6:23689 | DOI: 10.1038/srep23689
www.nature.com/scientificreports
KIR2DL2/2DL3-E35 alleles are 
functionally stronger than -Q35 
alleles
Rafijul Bari1, Rajoo Thapa1, Ju Bao2, Ying Li1, Jie Zheng2 & Wing Leung1,3
KIR2DL2 and KIR2DL3 segregate as alleles of a single locus in the centromeric motif of the killer cell 
immunoglobulin-like receptor (KIR) gene family. Although KIR2DL2/L3 polymorphism is known to 
be associated with many human diseases and is an important factor for donor selection in allogeneic 
hematopoietic stem cell transplantation, the molecular determinant of functional diversity among 
various alleles is unclear. In this study we found that KIR2DL2/L3 with glutamic acid at position 35 
(E35) are functionally stronger than those with glutamine at the same position (Q35). Cytotoxicity assay 
showed that NK cells from HLA-C1 positive donors with KIR2DL2/L3-E35 could kill more target cells 
lacking their ligands than NK cells with the weaker -Q35 alleles, indicating better licensing of KIR2DL2/
L3+ NK cells with the stronger alleles. Molecular modeling analysis reveals that the glutamic acid, 
which is negatively charged, interacts with positively charged histidine located at position 55, thereby 
stabilizing KIR2DL2/L3 dimer and reducing entropy loss when KIR2DL2/3 binds to HLA-C ligand. The 
results of this study will be important for future studies of KIR2DL2/L3-associated diseases as well as for 
donor selection in allogeneic stem cell transplantation.
Killer cell immunoglobulin-like receptors (KIRs) are expressed on the surface of most NK cells and a subset 
of T-cells1,2. The expression of KIR genes varies stochastically so that a single NK cell may express one to a few 
KIRs2,3. There are 15 KIR genes but only approximately 5% of individuals have all 15 KIR genes; others lack one 
or more genes4,5. Haplotypic variability in gene content is the result of gene duplication and deletion throughout 
evolution4,6. For example, KIR2DL2 appears to be an evolutionally newer fusion gene formed by unequal crossing 
between the extracellular domains of KIR2DL3 and the intracellular tail of KIR2DL17. Segregation analysis show 
that KIR2DL2 and KIR2DL3 actually behave as alleles at a single locus (KIR2DL2/3)8. Since their ligand-binding 
domains are highly homologous, KIR2DL2 and KIR2DL3 bind a similar set of HLA-C ligands. Functionally, it has 
been suggested that KIR2DL2 is a stronger receptor for HLA-C compared to KIR2DL3 in general9,10.
Twelve alleles have been identified for KIR2DL2 and 24 alleles for KIR2DL3 thus far. The allelic variations 
may generate further functional differences. For example, we have shown previously that KIR2DL1 alleles with 
arginine in position 245 of the transmembrane domain (KIR2DL1-R245) are stronger than those with cysteine 
(KIR2DL1-C245)11. In the Japanese population, 5 common KIR3DL1 allotypes, *001, *01502, *002, *005, and *007, 
have distinguishable inhibitory capacity, frequency of cellular expression, and level of cell-surface expression12. 
Carr et al. showed that the presence of arginine (R) at position 238 in the D2 domain and isoleucine at position 
320 in the transmembrane domain of the KIR3DL1*002 allele makes it a stronger receptor than the *007 allele 
that has glycine (G) and valine (V) at those positions13.
Although the molecular determinants of KIR2DL2/L3 functional diversity have not been elucidated, Frazier 
et al. have shown differential affinity and avidity of some common KIR2DL2 and KIR2DL3 alleles toward their 
HLA-C ligands, using Surface Plasmon Resonance (SPR)14. Three KIR2DL2 alleles (*001, *003 and *006) showed 
higher ligand affinity and avidity when compared to two other KIR2DL3 alleles (*001 and *002) that had glu-
tamine at amino acid position 35 (Q35). Surprisingly, one KIR2DL3 family member (*005) that contains glutamic 
acid at the same position (E35) showed high affinity and avidity toward HLA-C ligand at a level similar to those 
of KIR2DL2 alleles14. In this study, we hypothesized that these differences in affinity and avidity would translate 
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to biologic relevance in NK cell function. We investigated whether position 35 could be a useful biomarker to 
distinguish stronger versus weaker KIR2DL2/L3 for clinical uses.
Results
KIR2DL2/L3-E35 is functionally stronger than -Q35. The majority of KIR2DL2 alleles have glutamic acid 
at position 35 (E35) except KIR2DL2*004, whereas approximately half of the KIR2DL3 alleles contain glutamine 
at the same position (Q35) (Table 1). KIR2DL2 was reported to have higher affinity towards HLA-C ligands and 
stronger function than KIR2DL3 in general9,14, however, KIR2DL3*005 allele with E35 has affinity and avidity 
towards their HLA-C ligands similar to those of KIR2DL2 alleles14. We therefore hypothesized that position 35 
could be a molecular determinant of KIR2DL2/L3 functional strength. We developed a single nucleotide polymor-
phism (SNP) assay that has the ability to distinguish KIR2DL2/L3-E35 from KIR2DL2/L3-Q35. We typed 10 donors 
for the presence of alleles encoding KIR2DL2/L3-E35 and -Q35 (Fig. 1A) and validated the results by sequencing.
Next, we assessed the functional activities of single KIR2DL2/L3+ NK cell subset (i.e. KIR2DL1−KIR3 
DL1−NKG2A−) from 14 normal donors with different KIR2DL2/L3 allelic groups by CD107 degranulation assay. 
When stimulated with 721.221 cells lacking HLA-C ligands, KIR2DL2/L3-E35/E35 NK cells showed significantly 
higher degranulation than KIR2DL2/L3-Q35/Q35 NK cells (Fig. 1B,C). NK cells with KIR2DL2/L3-E35/Q35 showed 
intermediate degranulation (Fig. 1B,C). KIR2DL2/L3-E35/E35 NK cells also produced more interferon-γ (IFN-γ ) 
and granzyme B than KIR2DL2/L3-Q35/Q35 cells when stimulated with 721.221 cells (Supplementary Figure S1).
When NK cells with different KIR2DL2/L3 allelic groups were mixed with 721.221 cell expressing HLA-Cw07 lig-
ands, KIR2DL2/L3-E35/E35 NK cells showed significantly greater inhibition of CD107 degranulation than KIR2DL2/
L3-Q35/Q35 NK cells (Fig. 1D). KIR2DL2/L3-E35/Q35 NK cells had intermediate degranulation (Fig. 1D). These results 
suggest that KIR2DL2/L3-E35 is functionally stronger than KIR2DL2/L3-Q35 and there is a dosage effect.
Functional differences between different KIR2DL2/L3 allelic groups are independent of self C1 
ligand, KIR2DL2/L3 genotype or other NK receptor phenotype. Since NK cell responsiveness to 
missing self is regulated by licensing effect of self-ligand15,16, we examined the HLA-C1/C2 genotypes among 
the 14 donors (Supplementary Figure S2). Of the 14 donors, one was C2/C2 and his KIR2DL2/L3+ NK cells 
**
Alleles D1 D2 ST TM CYT
E35 11 16 35 41 50 114 123 131 148 167 200 208 216 221 225 232 236 239 245 248 254 260 266 268 269 272 282 296 298 312 320
32.0 L2*001 L R E R H P S R C G I P K R I V F de R S A S A S E D T R S A N
0 L2*002 – – – – – – – – – – – – – – – – – – – – – – – R Q - – – – – –
20.2 L2*003 – – – – – – – – – – T – – – – – – – – – – – – – – – – – – T –
0 L2*005 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – T –
0 L2*006 – P – – – – – – – – T – – – – – – – – – – – – – – – – – – T –
NA L2*007 – – – – – – – – – – – – – – – – A – – – – – – – – – – – – – –
NA L2*008 – – – – – – – – – – – – – – – – – – – C – – – – – – – – – T –
NA L2*009 – – – – – – – – R – T – – – – – – – – – – – – – – – – – – T –
NA L2*010 – – – – – – – – – – – – – – – – – – – C – – – – – Y – – – T –
0 L3*004 R P – – R – – – R – T – – I V – – L – C V P V R – – A H – T
7.8 L3*005 R P – – R – – – R – T – E – V – – L – C V P V R – – A H – T
NA L3*010 R P – – R – – – R – T – E – V – V L – C V P V R – – A – – T #
NA L3*014 – P – – R – – – R – T – E – V – – L – C V P V R – – A – – T
NA L3*015 – P – – – – – – R – T L E – V – – L – C V P V R – – A H – T
NA L3*016 – P – – – – N – R – T – E – V – – L – C V P V R – – A – – T
NA L3*017 – P – – R – – – R – T – E – V – – L – C V P V R – – A – – T #
Q35
1.7 L2*004 – P Q T – – – – – D T – E – – – – – – – – – – I – – – H – T S
71.6 L3*001 – P Q – – – – – R – T – E – V – – L – C V P V R – – A – – T
35.6 L3*002 – P Q – – – – – R – T L E – V – – L – C V P V R – – A H – T
1.1 L3*003 – P Q – – – – – R – T – E – V – – L – C V P V R – – T – – T
1.1 L3*006 – P Q – – – – – R – T – E – V – – L – C V P V R – – A H – T
NA L3*007 – P Q – – – – – R – T L E – V – – L – C – – – – – – A H – T
NA L3*009 – P Q – – – – – R – T – E – V – – L – C V P V R – – A – – T
NA L3*011 – P Q – L – – – R – T – E – V – – L – C V P V R – – A – – T
NA L3*012 – P Q – – – – – R – T – E – V – – L – C – P V R – – A H F T
NA L3*013 – P Q – – – – Q R – T – E – V – – L – C P P V R – – A – – T
Table 1.  KIR2DL2/L3 alleles are grouped based on the presence of glutamic acid or glutamine at position 35. 
**indicates percentage of individuals that have the KIR allele in Brazil Belo Horizonte Caucasian (http://www.
allelefrequencies.net/kir6002a.asp). “–” indicates identity with consensus to KIR2DL2*001; #alleles has few 
more amino acids “RSKVV SCPX”.
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had low CD107 degranulation (Fig. 2A), in part because the cells were unlicensed and had the weakest Q35/Q35 
combination. Of the other 13 C1+ donors, the level of CD107 degranulation appeared to follow the pattern of 
EE > EQ > QQ, rather than C1C1 > C1C2. These results suggest that the observed functional differences in E35 
and Q35 may be independent of ligand effect, although a larger number of individuals in each group will need to 
be studied to rule out an effect of the HLA-C haplotypes.
Because the most common KIR2DL2 alleles contain E35 and KIR2DL3 alleles contain Q35 (Table 1), we sought 
to determine whether it is clinically sufficient to genotype donors as KIR2DL2/L2, KIR2DL2/L3 and KIR2DL3/
L3 (corresponding to centromeric B score of 2, 1, 0, respectively), rather than grouping them into EE, EQ and 
QQ respectively. To address this question, we genotyped KIR2DL2 and KIR2DL3 using SSP-PCR17. Of the 4 EE 
donors, 2 were KIR2DL2/KIR2DL2 and 2 were KIR2DL2/KIR2DL3 (Fig. 2B,). All the QQ donors were KIR2DL3/
KIR2DL3. Of the 5 EQ donors, 3 were KIR2DL2/KIR2DL3 and 2 were KIR2DL3/KIR2DL3. These results suggest 
that E35 is common in many KIR2DL3 alleles and E35/Q35 SNP analysis is essential for KIR2DL2/L3 functional 
typing.
Besides KIR2DL2/L3, NK cells may express many other activating and inhibitory receptors that can also influ-
ence their functions. In this regard, Schonberg et al. reported that the presence of KIR2DL2 causes a major 
reduction in the frequency of NK cells expressing KIR2DL1 independent of the presence or absence of the C1 
or C2 epitope10. Therefore, we analyzed the expression of various NK cell receptors in donors with different 
allelic groups of KIR2DL2/L3. Although there was natural variation in the expression of different NK receptors 
among different donors, we did not observe any statistically significant association with different allelic groups 
of KIR2DL2/L3 (Fig. 2C). Thus, the functional difference between E35 and Q35 alleles could not be accounted by 
linkage disequilibrium with other NK cell receptor expression.
Substitution of glutamic acid with glutamine significantly reduces the functional strength 
of KIR2DL2*001. To directly demonstrate the effect of E35/Q35 polymorphism without potential influ-
ence from other known and unknown receptors expressed on polyclonal NK cells, monoclonal YT-Indy cell 
line was transfected with KIR2DL2*001 or a KIR2DL2*001 mutant with glutamine substituting glutamic acid at 
position 35 (KIR2DL2*001 E35Q). Stable cell lines with similar level of KIR2DL2/L3 expression were sorted by 
flow cytometer (Fig. 3A) and subjected to further functional analysis. Stable 721.221 cell line transduced with 
HLA-Cw07 (721-Cw7) ligands (Fig. 3B) was used as target cells. KIR2DL2*001 (E35) strongly inhibit the cyto-
toxicity of YT-Indy in the presence of HLA-Cw07 but the substitution of glutamic acid with glutamine at amino 
Figure 1. KIR2DL2/L3-E35 is functionally stronger than KIR2DL2/L3-Q35. (A) A single nucleotide 
polymorphism assay was developed to detect the presence of glutamic acid or glutamine at position 35 of 
KIR2DL2/L3 alleles. (B) Representative CD107 degranulation assays in which single KIR2DL2/L3+ NK cells 
were tested for missing-self recognition using 721.221 cells without C1 ligand. (C) Summary results of CD107 
degranulation assay from 4–5 donors with each allelic group. (D) CD107 inhibition by different KIR2DL2/L3 
allelic groups when stimulated with 721.221 cells expressing Cw07 ligand. Percentage indicates relative value 
when compared with target cells without Cw07 ligand. Results are average from 4–5 donors in each KIR2DL2/
L3 allelic group. P values were calculated using Student T test. Error bars represent SD.
www.nature.com/scientificreports/
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acid position 35 (E35Q) resulted in a weaker inhibitory receptor (Fig. 3C). As expected, there were no significant 
functional differences among mock, KIR2DL2*001 or a KIR2DL2*001 mutant against MHC-I deficient 721.221 
cells (Supplementary Figure S3).
In vivo anti-tumor activity of YT-Indy cells expressing different KIR2DL2/L3 alleles and 
mutants. A mouse model was used to assess the anti-tumor activity of YT-Indy cells expressing different 
KIR2DL2/L3 alleles against 721.221 target cells expressing HLA-Cw07 ligand and luciferase. On day one, 8- to 
12-week-old NSG mice were injected intraperitoneally with 5 × 105 target cells. Next day, YT-Indy cells express-
ing either KIR2DL3*001 (Q35), KIR2DL3*005 (E35), KIR2DL2*001 (E35) or KIR2DL2*001-E35Q mutant were 
injected at a 10:1 E/T ratio. After 2 weeks, the bioluminescence signals of the mice that were injected with target 
cells only showed the highest signal whereas the group injected with YT-Indy cells containing empty vector 
(mock) showed the lowest signal (Fig. 4A). KIR2DL3*001 (Q35) showed less inhibition than KIR2DL3*005 (E35). 
While KIR2DL2*001 (E35) showed strong inhibition (Fig. 4A,B), mutation of E35 to Q35 in KIR2DL2*001 mark-
edly reduced inhibition to level similar to those of KIR2DL3*001 (Q35), suggesting that E35 is essential for durable 
inhibition in vivo.
Molecular modeling analyses suggest glutamic acid at position 35 of KIR2DL2/L3 forms hydro-
gen bond with histidine at position 55. To understand the structural mechanism, we performed molec-
ular dynamic simulations on KIR2DL2*001-E35 and KIR2DL2*001-Q35 dimers. Overall, KIR2DL2*001-Q35 
showed substantially higher flexibility compared to KIR2DL2*001-E35 (Fig. 5A,B). Amino acid position 35 of 
KIR2DL2/L3 is located in the loop region and does not directly interact with either HLA binding or dimeriza-
tion interface. However, KIR2DL2/L3 alleles with E35 form strong electrostatic interactions with the side chain 
of histidine at position 55 (Fig. 5C), which significantly stabilized not only the loop regions but also the HLA 
binding interface. Destabilization of this region greatly increases the flexibility of both loop regions and HLA 
Figure 2. Functional differences between different KIR2DL2/L3 allelic groups are independent of self C 
ligand, KIR2DL2/L3 genotype, or other NK cell phenotype. (A) HLA-C ligands of 14 donors used for 
functional assay were genotyped using SNP assay and color coded. Blue  indicates HLA-C1 homozygous; red 
 indicates HLA-C1/C2 heterozygous; green  indicates HLA-C2 homozygous. (B) Donor KIR2DL2/L3 
genotyping were performed using SSP-PCR and are shown similarly in color code. (C) NK cell phenotype of 
donors with different groups of KIR2DL2/L3 alleles were analyzed by flow cytometry. P values were calculated 
using Student T test. Error bars represent SD.
www.nature.com/scientificreports/
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binding interface (Fig. 5D), which reduces the binding affinity of KIR2DL2/L3 with HLA by increasing entropy 
loss during binding. Since it has been shown earlier that KIR2DL2/L3 dimer stability significantly influences its 
binding affinity with its ligands, the simulation data supports the hypothesis that the observed functional differ-
ence between KIR2DL2/L3-E35 and -Q35 arises from the protein stability change caused by E35Q substitution.
Discussion
KIR genes are highly polymorphic in nature exhibiting haplotypic and allelic variations8,18. The allelic diversity in 
each KIR gene ranges from 7 in KIR2DS3 to 76 in KIR3DL118. Twelve KIR2DL2 alleles and 24 KIR2DL3 alleles 
have been identified thus far. Allelic variation may lead to functional diversity. For example a study by Moesta 
et al. reported that positions 16 and 148 accounted for KIR2DL2*001 being a stronger receptor for HLA-C ligand 
than KIR2DL3*0019. Schönberg K et al. showed that KIR2DL2 alleles might cross-react with HLA-C2 ligands but 
KIR2DL3 alleles could not10. A recent study by Fraizer et al. investigated the binding of 6 common KIR2DL2/L3 
alleles with their HLA-C ligands14. They found that KIR2DL3*005 (which has proline and arginine at position 
16 and 148 similar to those of KIR2DL3*001 but has glutamic acid at position 35 rather than glutamine) has 
affinity and avidity to HLA-C ligand as strong as KIR2DL2 alleles14. In line with these ligand-binding data, our 
functional cytotoxicity studies both in vitro and in vivo showed that KIR2DL2/L3 alleles with E35 are function-
ally stronger than Q35 alleles. NK cells licensed through stronger KIR2DL2/L3 alleles have higher cytotoxic-
ity than those with weaker alleles against tumor cells with missing ligands, a finding in line with our previous 
observation that KIR2DL1+ NK cells licensed through stronger KIR2DL1-R245 have higher cytotoxicity than 
KIR2DL1-C245 19,20.
KIR dimers are known to have higher affinity for HLA-C ligands than monomer. In the orthorhombic crys-
tals of KIR2DL2, Snyder et al. found that two receptor molecules with the same orientation dimerize in such 
a way that the amino-terminal D1 domain of one receptor packs against the carboxyl-terminal D2 domain of 
the other molecule with their strands in an approximate orthogonal orientation, creating a D1/D2 heterodi-
mer21. In another study, Fan et al. showed that covalently-linked KIR2DL1 dimer has higher affinity or avidity for 
HLA-Cw4 than monomer22. In the present study, molecular modeling analysis suggests that KIR2DL2/L3 alleles 
with the negatively charged E35 form electrostatic interactions with the positively charged H55 in KIR2DL2/L3 and 
Figure 3. Substitution of glutamic acid with glutamine at position 35 significantly reduces the functional 
strength of KIR2DL2*001. (A) Stable YT-Indy cell lines expressing KIR2DL2*001 or KIR2DL2*001 mutant 
with glutamic acid at the amino acid position 35 replaced with glutamine. YT-Indy transfected with empty 
vector was used as mock control. Similar expression of KIR2DL2/L3 in the cell lines was confirmed by flow 
cytometry. (B) 721.221 was stably transduced with MSCV vector containing HLA-Cw07 ligand. (C) Specific 
killing of YT-Indy expressing KIR2DL2*001 or KIR2DL2*001 mutants (2DL2 E35Q) were assessed against 
721.221-Cw07 by BADTA release assay. The experiments were repeated at least 3 times. P value was calculated 
using Student T test. Error bars represent SD.
www.nature.com/scientificreports/
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thereby stabilizes the binding with HLA-C ligands. On the contrary, KIR2DL2/L3 encoded by Q35 alleles lack the 
electrostatic interactions and show much higher structural flexibility in the KIR2DL2/L3 dimer thus providing an 
explanation for the much weaker ligand binding and inhibitory function.
Previous studies have shown that differences in KIR gene content are associated with the risk of many human 
diseases, including autoimmune diseases, inflammatory disorders, infectious diseases, immunodeficiency, cancer, 
and reproductive disorders23. KIR2DL2/L3 is specifically known to be associated with Crohn’s disease24, multi-
ple sclerosis25, chronic myeloid leukemia26, primary Sjogren’s syndrome27, lupus28, birdshot chorioretinopathy29, 
rheumatoid arthritis30, cervical intraepithelial neoplasia31, scleroderma32, and psoriasis33. KIR2DL2/L3 is also 
reported to be associated with herpes simplex virus 134 as well as human immunodeficiency virus 135 infections. 
Moreover, KIR2DL2/L3 are important determinant for donor selection in hematopoietic stem cell transplantation 
(HSCT). In this regard, we have previously showed that a single amino acid can be used to divide the KIR2DL1 
alleles into functionally strong and weak groups11. In the allogeneic HSCT setting, this biologic difference can 
be translated to markedly different patient survival and risk of leukemia relapse20. Taken together, our findings 
herein will have significant implications in donor selection and outcome evaluation in HSCT and NK cell therapy 
(KIR2DL1-R245 and KIR2DL2/L3-E35 are predicted to be favorable). The results will also be useful in setting the 
framework for future NK cell research in various clinical settings, including susceptibility and outcome of can-
cers, pregnancy complications, chronic viral infections, and autoimmune diseases.
Materials and Methods
Statement. Animal experiment was carried out according to the protocols that were approved by The 
Institutional Animal Care and Use Committee of St. Jude Children’s Research Hospital.
DNA constructs. Peripheral blood mononuclear cells were obtained from healthy human donors with 
informed consent under a protocol approved by the institutional review board at St Jude Children’s Research 
Hospital, in accordance with the Declaration of Helsinki. Total RNA was extracted from cells expressing 
KIR2DL2/L3 using RNA extraction kits (QIAGEN). cDNA of various alleles of KIR2DL2/L3 was generated from 
the RNA and cloned into mammalian expression vector pcDNA3 (Invitrogen). The identities of the KIR2DL2/L3 
alleles were confirmed by sequencing. Specific amino acids were substituted into KIR2DL2/L3 using recombinant 
polymerase chain reaction. HLA-Cw7 cDNA was amplified from a normal human peripheral blood cDNA pool as 
described for KIR2DL2/L3 alleles, confirmed by sequencing, and cloned into retroviral vector MSCV-IRES-GFP 
(received from vector laboratory, St Jude Children’s Research Hospital).
Figure 4. Effector cells expressing KIR2DL2/L3-E35 showed stronger inhibition than those with KIR2DL2/
L3-Q35 allele in vivo. YT-Indy cell line expressing different KIR2DL2/L3-E35, -Q35 or mutant alleles were 
injected in NSG mice with 721.221 target cells expressing HLA-Cw7 ligand and luciferase. (A) Bioluminescence 
pictures of mice after two weeks of injection. (B) Comparison of average bioluminescence signals among 
different groups of mice injected with YT-Indy cells carrying different KIR2DL2/L3 alleles. P values were 
calculated using Student T test. Error bars represent SD.
www.nature.com/scientificreports/
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Cell lines, culture, and transfection. YT-Indy cells (a generous gift from Dr. Zacharie Brahmi, Indiana 
University) were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1 mM penicillin/strep-
tomycin, 2 mM l-glutamine, 1 mM sodium pyruvate, and 1% minimum essential medium nonessential amino 
acids (Invitrogen). B-lymphoblastic cell line 721.221 was purchased from the International Histocompatibility 
Working Group and cultured in RPMI 1640 supplemented with 20% FBS and 1 mM penicillin/streptomycin. 
YT-Indy cells were transfected with pcDNA3 vector containing various KIR2DL2/L3 alleles by electroporation 
(Gene Pulser II; Bio-Rad). Stable cell lines were generated by selection in Geneticin (Invitrogen). The 721.221 
cells were transduced with retroviral vector MSCV-IRES-GFP containing HLA-Cw7. High-expressing cells was 
sorted by flow cytometric cell sorting using the monoclonal antibody (mAb) against HLA-C (One Lambda).
KIR2DL2/L3 single nucleotide polymorphism (SNP) and genotyping assay. To detect the pres-
ence of various alleles of KIR2DL2/L3 with glutamic acid or glutamine at position 35, a single-nucleotide mis-
match detection assay was developed as described previously19,36. Briefly, primers for the assay were designed 
in such a way that they amplified all the alleles of the KIR2DL2/L3 gene as well as the amplicon containing the 
polymorphic region of interest. The forward primer was 5′ -CATCCTGCAATGTTGGTCAG-3′ and the reverse 
primer was 5′ -CAAGGTCTTGCATCATGGGA-3′ . The probe for KIR2DL2/L3 alleles with a glutamic acid at 
position 35 was 6Fam-CAGGTTTGAGCACT-MGBNFQ and for those with a glutamine at the same position was 
VIC-CAGGTTTCAGCACT-MGBNFQ. Each assay reaction mix contained a 250 nM probe concentration and 
100 ng of genomic DNA in 1× TaqMan genotyping master mix (Applied Biosystems). The assay was performed 
on an HT7900 Sequence Detection System (Applied Biosystems) following the allelic discrimination assay pro-
tocol provided by the manufacturer. KIR2DL2/L3 genotyping was performed by a PCR-SSP method as described 
previously17.
Flow cytometry. The expression of KIR2DL2/L3 and other NK cell receptors were analyzed using flow 
cytometry. The following clones of antibody were used for phenotypic analysis: anti-CD158ah (11PB6, EB6.B), 
anti-CD158b (CH-L, GL183), anti-CD158e (DX9), anti-DNAM-1 (DX11), anti-CD11a (HI111), anti-NTBA 
(292811), anti-CD244, anti-CD3 (SK7, UCHT1), anti-granzyme B (GB10), anti-NKG2a (Z199), anti-NKp30 
(Z25), anti-NKp44 (Z231), anti-NKp46 (BAB281), anti-NKG2D (1D11), anti-CD56 (MY31, N901), and 
Figure 5. Structural effects of KIR2DL2-E35Q substitution. The effects of E35Q substitution in KIR2DL2 
in MD simulations are shown in (A) KIR2DL2*001-E35 and (B) KIR2DL2*001-Q35. KIR monomer binding 
to HLA ligand is shown in sausage representation. The other KIR monomer and HLA are shown in cartoon 
representation. Larger radii and warmer color indicate higher flexibility. Residues at positions 35 and 55 are 
shown in sphere. E35Q not only significantly destabilizes its adjacent regions but also substantially increases 
the flexibility of HLA binding interface. (C) E35 is predicted to form hydrogen bond with H55 side chain, which 
may contribute to the stabilization of the KIR2DL2-E35 structure. (D) E35Q causes significant conformational 
flexibility change of KIR2DL2, shown by much higher RMSF of the mutant. E35Q substitution in KIR2DL2 
greatly destabilizes the adjacent regions of the protein, and changes the flexibility of KIR2DL2 and HLA ligand 
binding site. E35Q and other residues that are involved in KIR2DL2 and HLA ligand interaction are mapped to 
the KIR2DL2-HLA structure. The HLA binding site on KIR2DL2 is highlighted with a blue frame.
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anti-CD14 (MphiP9). Flow cytometry analyses were conducted with LSRII (BD Biosciences) and FlowJo 8.8.6 
software (Tree Star).
Cytotoxicity assay. To determine the functional differences amongst different KIR2DL2/L3 and mutated 
alleles, cytotoxic activity was measured by using the DELFIA BATDA reagent (PerkinElmer Life and Analytical 
Sciences) following the manufacturer’s instruction. BATDA-labeled B-lymphoblastic cell lines 721.221 with or 
without HLA-C ligands were used as target cells at an effector : target (E:T) ratio of 20:1 for 2 hours at 37 °C. 
The fluorescence signals were measured using a Wallac Victor 2 Counter Plate Reader (PerkinElmer Life and 
Analytical Sciences).
CD107 degranulation assay. NK cells were tested for their cytolytic potential with the CD107 degranula-
tion assay. Effector cells were cocultured with target cells at 1:1 ratio in the presence of anti-CD107-FITC or -APC 
antibodies. After 1 hour of co-culture, GolgiStop (BD Biosciences) was added and the cells were incubated for 4 
more hours. The cells were then harvested, stained, and analyzed for CD107.
In vivo experiments. Non-obese diabetic/severe combined immunodeficient (NOD/SCID) IL-2γc−/− mice, 
8- to 12-weeks old, were used as animal model. 721.221-Cw7-luciferase cells were used as target cells. Mice were 
γ -irradiated at a dose of 200 cGy 1 day prior to intraperitoneall injections of 5 × 105 721.221-Cw7 cells. On the 
following day, 5 × 106 YT-Indy cells expressing different KIR2DL2/L3 alleles (effector cells) were injected intra-
peritoneally (E:T = 10:1). Disease progression in the injected mice was monitored by bioluminescence imaging 
(Xenogen, PerkinElmer Life and Analytical Sciences). The mice were sacrificed when they displayed signs of 
significant tumor progression. The experiments were terminated after 3 weeks as bioluminescence reached sat-
uration point.
Molecular modeling. The structural effects of E35Q mutation of KIR2DL2 were simulated by molec-
ular dynamics simulation37. The dimer structure of both E35 and Q35 were derived from crystal structure of 
KIR2DL2-HLA complex (PDB ID: 1EFX)21,38. The TIP3P water solvent box with 10 angstroms from the protein 
were added to each system, and counterions were used for neutralizing the charges. Each system were thoroughly 
minimized and heated to 300 K, and simulated for 25 ns by Langevin dynamics. The backbones root mean squire 
fluctuations (RMSFs) of CA atoms were calculated to evaluate protein stabilities.
Statistical analysis. Statistical significance between 2 groups was calculated using Student T test. The nom-
inal significance level was set at 0.05.
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